UGT1A8
Basic information
Region (hg38): 2:233617633-233773300
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (22 variants)
- Crigler-Najjar syndrome type 1 (6 variants)
- Crigler-Najjar syndrome (4 variants)
- UGT1A1-related disorder (4 variants)
- Hyperbilirubinemia (2 variants)
- Gilbert syndrome (2 variants)
- Crigler-Najjar syndrome, type II (2 variants)
- Crigler-Najjar syndrome type 1;Gilbert syndrome;Crigler-Najjar syndrome, type II;Lucey-Driscoll syndrome (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the UGT1A8 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 19 | 24 | ||||
missense | 78 | 90 | ||||
nonsense | 6 | |||||
start loss | 0 | |||||
frameshift | 4 | |||||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 4 | |||||
splice region | 2 | 1 | 3 | |||
non coding | 15 | 11 | 225 | 55 | 35 | 341 |
Total | 26 | 23 | 312 | 75 | 35 |
Highest pathogenic variant AF is 0.0000919
Variants in UGT1A8
This is a list of pathogenic ClinVar variants found in the UGT1A8 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
2-233617729-A-G | not specified | Likely benign (May 26, 2024) | ||
2-233617808-A-T | not specified | Uncertain significance (Apr 13, 2022) | ||
2-233617849-C-T | not specified | Uncertain significance (Jan 24, 2023) | ||
2-233617942-A-G | not specified | Uncertain significance (May 06, 2024) | ||
2-233617967-A-T | not specified | Uncertain significance (Feb 05, 2024) | ||
2-233617969-C-T | not specified | Uncertain significance (Jul 25, 2023) | ||
2-233617970-G-A | not specified | Uncertain significance (May 05, 2023) | ||
2-233617987-G-A | not specified | Uncertain significance (Oct 10, 2023) | ||
2-233618001-G-C | not specified | Uncertain significance (Oct 20, 2023) | ||
2-233618011-G-A | not specified | Likely benign (Feb 15, 2023) | ||
2-233618045-C-A | not specified | Uncertain significance (Apr 19, 2023) | ||
2-233618045-C-T | not specified | Uncertain significance (Jul 19, 2023) | ||
2-233618048-A-G | not specified | Uncertain significance (Jun 26, 2023) | ||
2-233618060-A-G | not specified | Uncertain significance (Mar 30, 2024) | ||
2-233618066-T-C | not specified | Uncertain significance (Jan 09, 2024) | ||
2-233618153-C-A | not specified | Uncertain significance (Apr 30, 2024) | ||
2-233618158-G-A | not specified | Uncertain significance (Dec 27, 2022) | ||
2-233618177-T-A | not specified | Uncertain significance (Nov 08, 2022) | ||
2-233618198-C-T | not specified | Uncertain significance (Oct 12, 2021) | ||
2-233618215-A-G | not specified | Uncertain significance (May 20, 2024) | ||
2-233618233-T-C | not specified | Uncertain significance (Feb 22, 2023) | ||
2-233618320-G-A | not specified | Uncertain significance (Feb 12, 2024) | ||
2-233618330-G-A | not specified | Uncertain significance (Sep 29, 2023) | ||
2-233618428-G-A | not specified | Uncertain significance (Oct 12, 2022) | ||
2-233618463-G-T | not specified | Uncertain significance (Jan 30, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
UGT1A8 | protein_coding | protein_coding | ENST00000305208 | 5 | 13052 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00000326 | 0.803 | 125699 | 0 | 49 | 125748 | 0.000195 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.247 | 309 | 297 | 1.04 | 0.0000175 | 3498 |
Missense in Polyphen | 131 | 129.52 | 1.0114 | 1493 | ||
Synonymous | -0.219 | 126 | 123 | 1.03 | 0.00000800 | 1084 |
Loss of Function | 1.32 | 11 | 16.9 | 0.653 | 8.19e-7 | 203 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000370 | 0.000369 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000206 | 0.000202 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.000555 | 0.000555 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1. {ECO:0000269|PubMed:19545173}.;
- Pathway
- Retinol metabolism - Homo sapiens (human);Steroid hormone biosynthesis - Homo sapiens (human);Metabolism of xenobiotics by cytochrome P450 - Homo sapiens (human);Drug metabolism - other enzymes - Homo sapiens (human);Drug metabolism - cytochrome P450 - Homo sapiens (human);Porphyrin and chlorophyll metabolism - Homo sapiens (human);Chemical carcinogenesis - Homo sapiens (human);Ascorbate and aldarate metabolism - Homo sapiens (human);Pentose and glucuronate interconversions - Homo sapiens (human);Estrogen Metabolism Pathway;Tamoxifen Pathway, Pharmacokinetics;Tramadol Pharmacokinetics;Valproic Acid Pathway, Pharmacokinetics;Mycophenolic acid Pathway, Pharmacokinetics;Mycophenolic acid Pathway, Pharmacokinetics/Pharmacodynamics;Irinotecan Pathway, Pharmacodynamics;Mycophenolic Acid Metabolism Pathway;Morphine Metabolism Pathway;Morphine Action Pathway;Tramadol Metabolism Pathway;Codeine and Morphine Metabolism;Tamoxifen metabolism;Glucuronidation;Glucuronidation;Phase II - Conjugation of compounds;Biological oxidations;Metabolism;thyroid hormone metabolism II (via conjugation and/or degradation)
(Consensus)
Recessive Scores
- pRec
- 0.581
Intolerance Scores
- loftool
- rvis_EVS
- -0.42
- rvis_percentile_EVS
- 25.73
Haploinsufficiency Scores
- pHI
- hipred
- N
- hipred_score
- 0.112
- ghis
- 0.420
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.0701
Mouse Genome Informatics
- Gene name
- Ugt1a9
- Phenotype
Gene ontology
- Biological process
- fatty acid metabolic process;steroid metabolic process;coumarin metabolic process;retinoic acid metabolic process;negative regulation of catalytic activity;negative regulation of fatty acid metabolic process;negative regulation of steroid metabolic process;flavone metabolic process;flavonoid glucuronidation;xenobiotic glucuronidation
- Cellular component
- endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane;intracellular membrane-bounded organelle
- Molecular function
- retinoic acid binding;enzyme inhibitor activity;steroid binding;fatty acid binding;UDP-glycosyltransferase activity;glucuronosyltransferase activity;protein homodimerization activity;protein heterodimerization activity